EBS
$54.31
Emergent Biosolutions
($.51)
(.93%)
EBS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $1.82
Revenue:  $406.25 Mil
Wednesday
Feb 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EBS reports earnings?
Beat
Meet
Miss

Where is EBS's stock price going from here?
Up
Flat
Down
Stock chart of EBS
Analysts
Summary of analysts' recommendations for EBS
Score
Grade
Pivots
Resistance
$55.93
$55.41
$55.11

$54.59

Support
$54.29
$53.77
$53.47
Tweet
Growth
Description
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission - to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax? (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx Pharmaceutical